Pharmacy spend that holds its line.
Ballast Analytic gives organizations that carry financial risk for total cost of care clinical insight and claims-level analytics into pharmacy spend — the piece of the number they're accountable for, but rarely control.
Added clarity
You carry the risk. Pharmacy still moves like someone else's line item.
For organizations accountable for total cost of care, pharmacy is often the least visible, least controllable part of the number they're judged on.
Pharmacy sits outside your control
You carry the financial risk for total cost of care, but formulary and utilization rules are usually set upstream, by someone else.
Specialty drugs blur the line
Physician-administered drugs often move outside the review that governs the rest of pharmacy spend.
Signal arrives after the window to act has closed
Claims runout and lagged reporting mean pharmacy trend often surfaces after the performance period it belongs to has already closed.
A single trend number hides where the dollars moved
An aggregate total-cost-of-care figure does not show whether pharmacy is the reason a panel's cost curve bent up.
Four disciplines, one view of spend.
Each part of the offering feeds the same model, so pharmacy spend is reviewed as part of total cost of care, not as a line item nobody owns.
Clinical Insight
Evidence-based review of therapy decisions, prior authorization criteria, and step therapy, so every prescribing decision is held to the same clinical standard.
Formulary Management
Tier placement and coverage rules built to steer utilization toward clinically equivalent, lower-net-cost options, whether or not you hold the underlying contract.
Utilization Management
Active management of where spend concentrates: specialty categories, site of care, prescriber patterns, and outlier claims, with rules in place to intervene, not just observe.
Pharmacy Data Analytics
Claims and cost data reconciled into a single model, so drug spend is visible as part of total cost of care, not a separate ledger.
What surfaces once the data sits in one model.
Every engagement is different, but the review tends to open the same three doors.
01
A single view of where the dollars move
Claims, utilization, and cost data in one model instead of several, so drug spend is visible as part of total cost of care, not a separate ledger.
02
Leverage identified, even without the contract
Utilization rules, site-of-care steerage, and formulary input applied everywhere you have a seat at the table.
03
Utilization drift caught inside the performance period
Patterns get flagged as they form, not discovered for the first time after the period has closed.